These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 36842448)

  • 41. Pulmonology: CFTR modulators for cystic fibrosis.
    Bertoncini E; Colomb-Lippa D
    JAAPA; 2013 Feb; 26(2):59-60. PubMed ID: 23409389
    [No Abstract]   [Full Text] [Related]  

  • 42. Reduced Intestinal Inflammation With Lumacaftor/Ivacaftor in Adolescents With Cystic Fibrosis.
    Tétard C; Mittaine M; Bui S; Beaufils F; Maumus P; Fayon M; Burgel PR; Lamireau T; Delhaes L; Mas E; Enaud R
    J Pediatr Gastroenterol Nutr; 2020 Dec; 71(6):778-781. PubMed ID: 32740537
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.
    Talamo Guevara M; McColley SA
    Expert Opin Drug Saf; 2017 Nov; 16(11):1305-1311. PubMed ID: 28846049
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Overcoming health disparities in access to CFTR modulator therapies: One child's journey with cystic fibrosis.
    Januska MN; Langfelder-Schwind E; Berdella MN
    Pediatr Pulmonol; 2022 Sep; 57(9):2273-2275. PubMed ID: 35637164
    [No Abstract]   [Full Text] [Related]  

  • 45. Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis.
    Deeks ED
    Drugs; 2016 Aug; 76(12):1191-201. PubMed ID: 27394157
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Elexacaftor-tezacaftor-ivacaftor overdose in an adolescent female with cystic fibrosis.
    Lyman BC; Seay J; Contreary C; Savant AP; Dell ML; Hescock GC
    Pediatr Pulmonol; 2022 Dec; 57(12):3174-3176. PubMed ID: 35962539
    [No Abstract]   [Full Text] [Related]  

  • 47. Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion.
    Colombo C; Foppiani A; Bisogno A; Gambazza S; Daccò V; Nazzari E; Leone A; Giana A; Mari A; Battezzati A
    J Endocrinol Invest; 2021 Oct; 44(10):2213-2218. PubMed ID: 33586024
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.
    Moheet A; Beisang D; Zhang L; Sagel SD; VanDalfsen JM; Heltshe SL; Frederick C; Mann M; Antos N; Billings J; Rowe SM; Moran A;
    J Cyst Fibros; 2021 Mar; 20(2):333-338. PubMed ID: 32917547
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study.
    Bell SC; Mainz JG; MacGregor G; Madge S; Macey J; Fridman M; Suthoff ED; Narayanan S; Kinnman N
    BMC Pulm Med; 2019 Aug; 19(1):146. PubMed ID: 31409396
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
    Mayer-Hamblett N; Boyle M; VanDevanter D
    Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ivacaftor withdrawal syndrome: A potentially life-threatening consequence from a life-saving medication.
    Clegg JM; Malloy KW; Brown RF; Grisso AG; Sokolow AG
    J Cyst Fibros; 2022 May; 21(3):549-550. PubMed ID: 34391678
    [No Abstract]   [Full Text] [Related]  

  • 52. Exhaled nitric oxide in stable adult cystic fibrosis patients, during exacerbation and following CFTR-modifying treatment.
    Vincken S; Verbanck S; De Wachter E; Vanderhelst E
    Eur Respir J; 2019 May; 53(5):. PubMed ID: 30819814
    [No Abstract]   [Full Text] [Related]  

  • 53. Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor.
    Rubin JL; O'Callaghan L; Pelligra C; Konstan MW; Ward A; Ishak JK; Chandler C; Liou TG
    Ther Adv Respir Dis; 2019; 13():1753466618820186. PubMed ID: 30803355
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New Drug Hailed as Major Breakthrough in Cystic Fibrosis.
    Am J Med Genet A; 2020 Jan; 182(1):8-9. PubMed ID: 31825178
    [No Abstract]   [Full Text] [Related]  

  • 55. Cystic fibrosis--what are the prospects for a cure?
    Kumar S; Tana A; Shankar A
    Eur J Intern Med; 2014 Nov; 25(9):803-7. PubMed ID: 25447947
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of CFTR-modulating drugs on GH-IGF-1 axis impairment in adult patients with cystic fibrosis.
    Pascucci C; De Biase RV; Savi D; Quattrucci S; Gnessi L; Lubrano C; Lenzi A
    J Endocrinol Invest; 2019 Nov; 42(11):1361-1363. PubMed ID: 31006073
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor.
    Jennings MT; Dezube R; Paranjape S; West NE; Hong G; Braun A; Grant J; Merlo CA; Lechtzin N
    Ann Am Thorac Soc; 2017 Nov; 14(11):1662-1666. PubMed ID: 28406713
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies.
    Jennings MT; Flume PA
    Ann Am Thorac Soc; 2018 Aug; 15(8):897-902. PubMed ID: 29812963
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SIMPLIFYing cystic fibrosis treatment in a post-modulator era.
    Yang C
    Lancet Respir Med; 2023 Apr; 11(4):299-300. PubMed ID: 36463912
    [No Abstract]   [Full Text] [Related]  

  • 60. Tezacaftor for the treatment of cystic fibrosis.
    Sala MA; Jain M
    Expert Rev Respir Med; 2018 Sep; 12(9):725-732. PubMed ID: 30073878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.